Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial
Mats Christian Højbjerg Lassen,John W. Ostrominski,Silvio E. Inzucchi,Brian L. Claggett,Ian Kulac,Pardeep Jhund,Rudolf A. de Boer,Adrian F. Hernandez,Mikhail N. Kosiborod,Carolyn S.P. Lam,Felipe A. Martinez,Sanjiv J. Shah,Akshay S. Desai,Magnus Petersson,Anna Maria Langkilde,Kieran F. Docherty,John J.V. McMurray,Scott D. Solomon,Muthiah Vaduganathan
DOI: https://doi.org/10.1002/ejhf.3269
2024-05-16
European Journal of Heart Failure
Abstract:Effect of dapagliflozin in patients with type 2 diabetes (T2D) and heart failure (HF) with mildly reduced/preserved ejection fraction (HFmrEF/HFpEF) according to background glucose‐lowering therapy (GLT). HF, heart failure. CI, confidence interval; DPP4i, dipeptidyl peptidase 4 inhibitor; GLP‐1 RA, glucagon‐like peptide‐1 receptor agonist; HR, hazard ratio; T2DM, type 2 diabetes mellitus. Aims Type 2 diabetes (T2D) and heart failure (HF) frequently coexist, but whether clinical outcomes and treatment effects of sodium–glucose cotransporter 2 inhibitors (SGLT2i) vary in relation to background glucose‐lowering therapy (GLT) in this population is uncertain. Methods and results DELIVER randomized patients with HF and left ventricular ejection fraction (LVEF) >40% to dapagliflozin or placebo. The primary outcome was a composite of worsening HF (HF hospitalization or urgent HF visit) or cardiovascular death. In this pre‐specified analysis of participants with T2D, treatment effects were assessed by number and class of background GLT(s). Of 3150 participants with T2D at baseline, 22.9% were on no GLT, 36.5% were treated with 1 GLT, and 40.6% with ≥2 GLTs. During follow‐up (median: 2.3 years), treatment benefits of dapagliflozin (vs. placebo) on the primary outcome were consistent irrespective of the number of background GLTs (0 GLTs: hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.50–1.00; 1 GLT: HR 1.04, 95% CI 0.80–1.34; ≥2 GLTs: HR 0.71, 95% CI 0.56–0.90; pinteraction = 0.59). Similar findings were observed among participants with (HR 0.73, 95% CI 0.59–0.92) and without background metformin use (HR 0.89, 95% CI 0.72–1.11; pinteraction = 0.22) and in participants with (HR 0.89, 95% CI 0.69–1.16) and without background insulin use (HR 0.78, 95% CI 0.65–0.95; pinteraction = 0.45). Dapagliflozin was well‐tolerated irrespective of the number of background GLTs. Conclusions Dapagliflozin safely and consistently improved clinical outcomes among individuals with T2D and HF with LVEF >40% irrespective of the number and class of background GLTs, and the benefits were not influenced by concomitant metformin or insulin use. These data bolster contemporary guidelines supporting first‐line SGLT2i among individuals with T2D and HF, irrespective of background GLT.
cardiac & cardiovascular systems